Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Capital International Inc. CA

Key Points

• Capital International Inc. CA raised its stake in Zimmer Biomet by 37.3% in Q3, buying 40,666 shares to hold 149,707 shares worth about $14.75 million (≈0.08% ownership).
• Q results exceeded expectations: Zimmer Biomet reported EPS of $2.42 vs. $2.38 expected and revenue of $2.24B (+10.9% YoY), and set FY2026 guidance of $8.30–$8.45 EPS (analysts ~8.22).
• The company declared a quarterly dividend of $0.24 (annualized $0.96) payable April 30 with an ex-dividend date of March 31, implying a ~1.0% yield and a 27.1% payout ratio; the stock trades with a market cap near $17.96B and a P/E of 25.93.

Capital International Inc. CA increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 37.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 149,707 shares of the medical equipment provider's stock after purchasing an additional 40,666 shares during the quarter. Capital International Inc. CA owned 0.08% of Zimmer Biomet worth $14,746,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Key Financial Inc raised its holdings in shares of Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. boosted its holdings in shares of Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC grew its position in shares of Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 149 shares during the last quarter. Root Financial Partners LLC acquired a new stake in Zimmer Biomet during the third quarter worth about $31,000. Finally, Mather Group LLC. bought a new position in Zimmer Biomet in the third quarter worth about $36,000. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $91.78 on Wednesday. The stock has a market cap of $17.96 billion, a P/E ratio of 25.93, a P/E/G ratio of 1.91 and a beta of 0.58. The firm's 50-day simple moving average is $92.21 and its 200 day simple moving average is $95.41. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. During the same quarter in the prior year, the firm posted $2.31 EPS. Zimmer Biomet's revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is currently 27.12%.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. BTIG Research reaffirmed a "buy" rating and set a $112.00 target price on shares of Zimmer Biomet in a report on Tuesday, February 10th. Citigroup reissued a "buy" rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Robert W. Baird restated a "neutral" rating and set a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. UBS Group restated a "sell" rating and set a $89.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Finally, Wells Fargo & Company raised their target price on Zimmer Biomet from $93.00 to $98.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and a consensus price target of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.